The global condensing unit market is projected to reach $70.2 billion by 2035, growing at a 4.8% CAGR from 2026 to 2035. Growth is fueled by rising demand for energy-efficient cooling solutions, expanding refrigeration needs in food & beverage and pharmaceutical sectors, and increased adoption of IoT-enabled smart technologies. The Asia-Pacific region is expected to see the highest growth due to urbanization and infrastructure development. Innovations in eco-friendly refrigerants, smart monitoring, and modular designs are shaping the market's future, alongside strategic expansions in emerging markets and sustainability initiatives.
The global condensing unit market is forecast to reach $70.2 billion by 2035, growing at a 4.8% CAGR from 2026 to 2035. For readers following Industrials-sector stocks on Pluang, here is the market snapshot as of Nov 06, 2026 20:12 WIB: out of 135 priced US stocks, 75 rose and 54 fell. Notable movers include Comfort Systems USA Inc (FIX) up 6.02% at USD 1,023.00 with a typical hold time of 42 days and 98% buy orders, Nuscale Power Corporation (SMR) up 5.52% at USD 4.59 with 86% buy orders, and nVent Electric (NVT) up 5.39% at USD 103.68 with balanced buy/sell activity.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
